Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
$110.97
-$1.54(-1.52%)
At close: 4:00 PM EST
$110.97
-$1.54(-1.52%)
Day’s Range― - ―
52-Week Range$73.31 - $112.90
Previous CloseN/A
Volume3.30M
Average Volume (3M)13.01M
Market Cap
$275.53B
Enterprise Value$232.86B
Total Cash (Recent Filing)$18.21B
Total Debt (Recent Filing)$41.37B
Price to Earnings (P/E)14.7
Beta0.57
Next Earnings
Feb 03, 2026EPS Estimate
2.04Next Dividend Ex-DateN/A
Dividend Yield3.12%
Share Statistics
EPS (TTM)2.58
Shares Outstanding2,482,022,500
10 Day Avg. Volume11,995,181
30 Day Avg. Volume13,013,053
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda8.42
Forecast
1Y Price Target
$119.80Price Target Upside7.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)7.48
Revenue Forecast (FY)$67.87B
Bulls Say, Bears Say
Bulls Say
Keytruda Loss-of-exclusivity MitigationPlanned introduction of a patent-protected subcutaneous Keytruda formulation and a volume-focused strategy to compete with biosimilars could blunt revenue erosion from loss of exclusivity and support sales stability.
Pipeline Readouts And LaunchesMultiple upcoming data readouts and planned commercial launches for assets such as Welireg, TL1A, Restoret, sotatercept, Keytruda QLEX and Winrevair could provide sequential upside and help replace lost oncology revenue.
Strategic Acquisition And Infectious Disease ExpansionAcquisition of Cidara and Breakthrough Therapy designation for CD388, plus potential for preventative dosing and long patent protection, could create a new high-value infectious disease franchise with multi‑billion sales potential.
Bears Say
Acquisition Valuation And Clinical-readout RiskA high acquisition price for Cidara increases investor exposure to clinical risk ahead of a pivotal CD388 readout, raising the chance of share volatility if the trial does not confirm benefit.
Limited Clinical Impact Of DOR/ISL And Growth ClarityNon-inferiority of the two-drug DOR/ISL HIV regimen is unlikely to meaningfully change prescribing behavior, and ongoing uncertainty about durable growth beyond Keytruda exclusivity may continue to weigh on the stock.
Vaccines Volume And Pricing RiskCDC consideration of a single-dose Gardasil option combined with company commentary that price increases would not fully offset volume declines creates downside risk to vaccine revenue expectations.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $112.90 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $275.53B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 03, 2026 which is in 17 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 30, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.362 by $0.218.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 3.12%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.04.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,482,022,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.58 in its last earnings report, beating expectations of $2.362. Following the earnings report the stock price went down -0.349%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$119.80 (7.96% Upside)
$119.80 (7.96% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 736.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.03%
12-Months-Change
Fundamentals
Return on Equity
39.51%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.View all MRK earnings summariesMRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$119.80
▲(7.96% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
20.20% Mutual Funds
0.43% Other Institutional Investors
55.08% Public Companies and Individual Investors